Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens
- 20 November 2021
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (2) , 232-242
Abstract
Post-transplant cyclophosphamide (PTCy) combined with tacrolimus (TAC) as graft-versus-host disease (GvHD) prophylaxis post-hematopoietic cell transplantation (HCT) is safe and effective. Optimal serum levels of TAC in this combination remain undetermined. We hypothesized that TAC at initial steady state (TISS) of n = 172) or mismatched donors (n = 38), and flat dose (FD) or weight-based dose (WBD) TAC. Twenty-four-month overall survival (OS), disease free survival (DFS), and relapse rate (RR) were 61%, 56%, and 22%, respectively, in TISS < 10 ng/mL cohort (n = 176), and 50%, 43%, and 35%, respectively, in TISS ≥ 10 ng/mL cohort (n = 34) (OS, P = 0.71; DFS, P = 0.097; RR, P = 0.031). OS, DFS, RR, non-relapse mortality, acute GvHD grade II–IV, grade III–IV or chronic GvHD by TISS were similar in multivariable analysis. TISS ≥ 10 ng/mL conferred increased risk of viral infection (P = 0.003). More patients receiving FD vs. WBD had TISS < 10 ng/mL (P = 0.001). Overall, TISS < 10 ng/mL early post HCT conferred similar survival outcomes and lowered risk of viral infection and toxicities compared to TISS ≥ 10 ng/mL.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health
This publication has 30 references indexed in Scilit:
- Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host Disease ProphylaxisTransplantation and Cellular Therapy, 2013
- Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on OutcomeTransplantation and Cellular Therapy, 2010
- PRES (posterior reversible encephalopathy syndrome), a rare complication of tacrolimus therapyEmergency Radiology, 2008
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantationTransplantation and Cellular Therapy, 2004
- Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donorsBone Marrow Transplantation, 2003
- Practical considerations in the use of tacrolimus for allogeneic marrow transplantationBone Marrow Transplantation, 1999
- Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantationTransplantation and Cellular Therapy, 1998
- Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantationTransplantation and Cellular Therapy, 1998
- Serum Cyclosporine Concentration and Risk of Acute Graft-versus-Host Disease after Allogeneic Marrow TransplantationNew England Journal of Medicine, 1988